Eribulin | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Eribulin
US Patents

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Eribulin

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

24 API Suppliers, 15 USDMF, 2 JDMF, 1 KDMF, 10 NDC API, 12 Listed Suppliers, $ API Reference Price

24 API Suppliers
15 USDMF
2 JDMF
1 KDMF
10 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

14 Drugs in Development

14 Drugs in Development

INTERMEDIATES

10 Intermediate Suppliers

10 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

17 FDF Dossiers, 5 FDA Orange Book, 4 Europe, 2 Canada, 4 Australia, 1 South Africa, 1 Listed Dossiers

17 FDF Dossiers
5 FDA Orange Book
4 Europe
2 Canada
4 Australia
1 South Africa
1 Listed Dossiers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 41 News #PharmaBuzz

2 Data Compilation #PharmaFlow
41 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 3 Regulatory FDF Prices, 7 Annual Reports

1 US Medicaid Prescriptions
3 Regulatory FDF Prices
7 Annual Reports

MARKET PLACE

12 APIs, 3 FDF Dossiers

12 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 2 US Exclusivities, 1 Health Canada Patents

2 US Patents
2 US Exclusivities
1 Health Canada Patents

$ API Ref.Price (USD/KG) : 14,161,255 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

2 All

01 2EISAI INC

filter Patent Number Reset all filters

2 All

01 1RE46965

02 1RE46965*PED

filter API Patent Reset all filters

2 All

01 2Blank

filter FDF Patent Reset all filters

2 All

01 1Y

02 1Blank

filter Expiration Date Reset all filters

2 All

01 12027-01-08

02 12027-07-08

Product Main Page

01

EISAI INC

ERIBULIN MESYLATE

Next-Gen Conjugates

Not Confirmed

EISAI INC

Next-Gen Conjugates

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-01-08

ERIBULIN MESYLATE

US Patent Number : RE46965

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 201532

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-01-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

EISAI INC

ERIBULIN MESYLATE

Next-Gen Conjugates

Not Confirmed

EISAI INC

Next-Gen Conjugates

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-07-08

ERIBULIN MESYLATE

US Patent Number : RE46965*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 201532

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-07-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!